-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Cara Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
- Cara Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$5.99M, a 79.3% increase year-over-year.
- Cara Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$85.6M, a 28.8% increase year-over-year.
- Cara Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$121M, a 38.8% decline from 2022.
- Cara Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$87.5M, a 1.74% increase from 2021.
- Cara Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$89.1M, a 1754% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)